

CURRICULUM VITAE

NAME: Slobodan Paessler, D.V.M., Ph.D.

DATE: June 2013

PRESENT POSITION AND ADDRESS:

Professor with tenure, Department of Pathology
Director, Galveston National Laboratory Preclinical Studies Core
Scientific Director, ABSL-3 Facilities
University of Texas Medical Branch (UTMB)
301 University Boulevard, 5.200P GNL
Galveston, TX 77555-0609
Telephone: (409) 266-6913
FAX: (409) 747-0762
Email: slpaessl@utmb.edu

BIOGRAPHICAL:

HOME ADDRESS:	11646 Zingelmann Road, Galveston, TX, 77554, USA
MARITAL STATUS:	Married, 3 children
CITIZENSHIP	German citizen, USA-permanent resident

EDUCATION:

1987 – 1991	B.S., Veterinary Sciences, Agriculture and Veterinary School, Osijek, Croatia.
1993 – 1999	Veterinary Medicine (DVM), Ludwig-Maximilian-University, Munich, Germany.
1999 – 2002	Dr. Med. Vet. (PhD-like) Ludwig-Maximilian-University, Munich, Germany. Thesis: "Detection of antibodies against alphaviruses in sera of human and animal origin using recombinant antigens and virus-specific monoclonal antibodies." Funded by FHG (Fraunhofer Gesellschaft), Germany.
2003 – 2007	Ph.D. in Experimental Pathology, "Pathogenesis of Venezuelan equine encephalitis virus", UTMB Graduate School of Biomedical Sciences, Galveston, TX, USA.

SPECIAL TRAINING:

12/2002 – 02/2003	Large animal ABSL-3 training at CSU, Fort Collins, Colorado
01/2005 – 10/2005	BSL-4/ABSL-4 training at UTMB
02/2006 – present	GLP training for high containment laboratories

PROFESSIONAL AND TEACHING EXPERIENCE:

1991 – 1993	Veterinary Technician, Ludwig-Maximilian-University, Munich, Germany
1999 – 2001	Research Assistant (Candidate for scientific degree in veterinary medicine), Dept. of Microbiology, Ludwig-Maximilian-University, Munich, Germany
2002 – 2003	Post-doctoral Fellow (NIH Trainee, T32), Department of Pathology, UTMB, Galveston, TX
2004 – 2008	Assistant Professor/NIH Career Award, Department of Pathology, UTMB, Galveston, TX
2004 – Present	Animal work/necropsy training program for ABSL-3/4, UTMB, Galveston, TX
2005 – Present	Director, Galveston National Laboratory Preclinical Studies Core, UTMB, Galveston, TX

2005 – Present	Scientific Director, ABSL-3 facilities, Department of Pathology, UTMB, Galveston, TX
2008 – Present	Associate Professor, Department of Pathology, UTMB, Galveston, TX
2010 – Present	Associate Professor with tenure, Department of Pathology, UTMB, Galveston, TX
2012 – Present	Professor with tenure, Department of Pathology, UTMB, Galveston, TX

RESEARCH ACTIVITIES:

Areas of research: Molecular biology, viral pathogenesis, viral ecology, vaccine/antivirals, and diagnostics development.

Current Research Awards:

1R01AI-10-003 National Institutes of Health (NIAID): Recombinant vaccine against Argentine hemorrhagic fever virus, PI **S. Paessler**, 25% effort, \$4,800,000 total funding, from 04/04/2011 through 04/03/2016.

1R01AI08764301-A1, NIH/NIAID, Reverse genetics to develop a second generation of Rift Valley fever vaccine, **PI: T Ikegami (S. Paessler Co-PI)**, 1,250,000 (direct cost) from 12/14/2010 through 11/30/2015.

1UC7AI070083, National Institutes of Health (NIAID), “Galveston National Laboratory Operations, Preclinical Studies Core,” National Laboratory PI: J. LeDuc, **Core Director: S Paessler**, 50% effort, \$2,967,402 for the Preclinical Studies Core from 05/03/2011 through 04/30/2016.

U54 AI057160, National Institutes of Health (NIAID), Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, PI: SL Stanley. Project: “Stat 1 modification of antiviral defense,” Project Leader: W. Holtzman, **PI for the subcontract S Paessler**, 5% effort, \$96,000/year, from 03/01/2009-02/28/2014.

U54 AI065357, National Institutes of Health (NIAID), Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, PI: J Belisle. Project: “Arenavirus entry and its inhibition,” Project Leader: J Nuerenberg, **PI for the subcontract S Paessler**, 2% effort, \$80,000/year from 03/01/2009-02/28/2014.

No number, Celgene, Inc. “Novel antiviral strategy against arenaviruses”. PI: **S. Paessler**, no salary effort, \$64,000 total from 09/2011-06/2013.

W81XWH-13-C-0092, Dept. of Army, “Chimeric Alphaviruses for Serological VEEV Diagnostics”, 1) To create chimeric viruses encoding nonstructural Sindbis virus (SINV) and structural VEEV (TC83 and TrD strains) proteins that replicate efficiently in vitro but are highly attenuated in vivo. 2) To test the chimeric viruses in murine model for their attenuation, using intracranial challenge route. 3) To compare the chimeric viruses to the VEEV parent viruses in a variety of serological tests (to be done at USAMRIID), PI: **S. Paessler**, 5% effort, \$320,000 total from 10/01/12-09/30/15

Student fellowships/honors:

Katherine Taylor, graduate student fellowship: U.S. Department of Homeland Security, “FAZD Center STEM Career Development Program”, \$96,035, from 09/30/07-09/29/2011

Ivan Kurolt, European Union Student Fellowship (Croatia) for Infectious Diseases, from 02/2009-6/2010.

Alexey Seregin, Graduate student fellowship: NIH (T32), from 09/2011-09/2013.

Olga Kolokoltsova, Sealy Center for Vaccine Development pre-doctoral fellowship, University of Texas Medical Branch, Galveston, TX, 2011-2012.

Olga Kolokoltsova, Bromberg Scholar, University of Texas Medical Branch, Galveston, TX, 2011-2012.

Olga Kolokoltsova, Robert Bennett Tuition Scholarship, University of Texas Medical Branch, Galveston, TX, 2011.

Olga Kolokoltsova, Zhou Sisters Great Expectations Scholarship, University of Texas Medical Branch, Galveston, TX, 2011.

Pending grants

NIAID U19 Center of Excellence for Translational Research in Biodefense, entitled "Developing Vaccines for Highly Pathogenic RNA Viruses via a Novel Delivery Vector." **PI: S Paessler.**

Partnerships for Biodefense (R01) RFA-AI-13-013, entitled "Universal flu vaccine." **PI: S Paessler**

Partnerships for Biodefense (R01) RFA-AI-13-013, entitled, "Advanced Multivalent Lassa Virus Vaccine." **PI: S Paessler**

Previous Research Awards:

T32 CA107536, National Institutes of Health, Training Grant in Infectious Diseases, "VEE pathogenesis in equines," **PI: S Paessler**, \$84,000, 04/01/2002 through-12/31/2003.

U54 AI057156, National Institutes of Health, Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE), Developmental Project: "Chimeric Alphaviruses for Serological VEEV Diagnostics", Overall PI: Walker, **Project PI: S Paessler**, \$200,000, 5% effort, from 05/01/2004 to 04/30/2006.

U54 AI057156, National Institutes of Health, Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE), **Developmental Project PI: S Paessler**: "Morpholino Antivirals against VEEV," Overall PI: Walker, **Project PI: Paessler**, \$200,000, 5% effort, from 05/01/2004 to 04/30/2006.

No number, Implicit Bioscience, "Test one antiviral compound against avian influenza," **PI: S Paessler**, \$30,386, 1% effort, from 12/01/2005 through 08/31/2006.

No number, Implicit Bioscience, "Test one antiviral compound against Junin virus," **PI: S Paessler**, 1% effort, \$34,386, from 12/01/2006 through 10/3/2007.

No number, SciClone Pharmaceuticals, "Immunomodulators as potential therapeutics against influenza viruses," **PI: S Paessler**, \$38,000, 1% effort, from 07/01/2006 through 09/30/2006.

N01-AI30065-Part C (15), National Institutes of Health, "In vitro and animal models for emerging diseases and biodefense: evaluation of candidate influenza antiviral products in a ferret model," PI: Stanberry, **PI for the task order: S Paessler**, no salary, \$1,446,549, from 10/01/2005 to 09/30/2007.

No number, Kirin Pharma USA, Inc., "Human monoclonal anti-M2e antibody for treatment of influenza infections", **PI: S Paessler**, 1% effort, \$26,000, from 09/23/2007 through 12/31/2007.

5K08AI059491, National Institutes of Health, "VEE pathogenesis and vaccine development," **PI: S Paessler**, 75% effort, \$445,298, from 04/01/2004 to 03/31/2008. This is a competitive career award for young clinical investigators.

5R01AI053135, National Institutes of Health, "A Sindbis virus-based vaccine against RVFV infection," PI: I. Frolov, **Co-PI S Paessler**, no salary, \$60,000, from 04/15/2003 to 03/31/2008.

No number, Novavax, "H3N2 VLP Vaccine Immunogenicity and Efficacy Study in Ferrets," **PI: S Paessler**, 1% effort, \$115,118, from 09/01/2006 through 06/20/2008.

No number, Cytogenix Inc., "Test DNA vaccine against avian influenza," **PI: S Paessler**, 2% effort, \$90,883, 05/01/2006 through 06/30/2008.

No number, REPLICor Technologies, Inc., "Test two compounds against Rift Valley fever virus," **PI: S Paessler**, 1% effort, \$12,000, from 10/23/2006 through 06/30/2008.

5R44AI056525, National Institutes of Health (SBIR), "Antivirals against Arenaviruses," PI: Hruby, **PI for the subcontract S Paessler**, no salary, \$557,900, from 11/01/2005 to 10/31/2008.

No number, Influmedix, Inc., "Antiviral therapeutics against influenza A viruses," **PI: S Paessler**, 1% effort, \$27,952, from 09/23/2007 through 30/12/2008.

No number, Novavax, Inc., "H3N2 VLP vaccine immunogenicity and efficacy study in ferrets," **PI: S Paessler**, 1% effort, \$62,411, from 09/01/2006 through 06/20/2009.

No number, Kyowa Hakko Kirin California, Inc., "Test human monoclonal anti-M2e antibody for treatment of influenza (H5N1) infections in mice," **PI: S Paessler**, 1% effort, \$59,963 from 06/01/2008 through 06/30/2009.

Gates Foundation, "Vaccine development against epidemic and potentially pandemic influenza," PI: C. Turley, **Program Director for Preclinical Trials: S Paessler**, \$9,500,000 (\$759,000 for preclinical trials), 10% effort (no salary), 02/01/2007 through 10/31/2009.

No number, AVI Biopharma (DoD contract). "Investigation of anti-Junin virus activity of four Arenavirus targeting PPMO", PI: **S Paessler**, 2% effort, \$365,000, from 04/08/2008 through 11/30/2009.

No number, Kirin Pharma USA, Inc., "Development of human monoclonal anti-M2e antibody for treatment of influenza (H5N1) infections in mice," **PI: S Paessler**, 1% effort, \$59,963, from 05/31/2008 – 11/30/2009.

5R43AI068248-02, National Institutes of Health (NIAID), PI: R. Whalen, "Vaccines for Eastern and Western Equine Encephalitis Viruses", 2% effort, \$81,000 **PI: S Paessler** for the subcontract 06/2009-09/2010.

N01-AI30065-Part E (02), National Institutes of Health, "In vitro and animal models for emerging diseases and biodefense: antibody production in ferrets," PI: Mark Estes, **PI for the task order: S Paessler**, no salary, \$1,046,549, from 10/01/2005 to 09/30/2010.

No Number, Vaxart, Inc. "Animal model for swine flu", **PI: S Paessler**, no salary/effort, total \$34,000 from 11/01/09-10/30/2010.

No number, VaxInnate Corporation, "Support completion of pre-clinical development of vaccine and evaluate the efficacy of vaccine in the animal model against challenge with influenza A viruses," **Program PI: S Paessler**, 1% effort, \$713,811, from 09/01/2006 through 12/6/2010.

No number, Hemispherx Biopharma, Inc., "Antiviral effect of human IFN-a and TLR3 agonists against influenza A viruses," **PI S Paessler**, no salary/effort, \$59,000 total from 07/17/2009-012/17/2010).

2U54 AI057156-06, National Institutes of Health (NIAID), Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, PI: D Walker. Developmental Project "Recombinant genetics for the Junin virus," **Project Leader: S Paessler**. 2% effort, \$120,000/year from 03/01/2009-02/28/2011.

IHII pilot grant, "Quantitative monitoring of the innate immune response in Arenaviridae infections", PI: A. Brasier, **Co-I: S Paessler**, 11/01/2010-08/30/2011.

ITS Novel Method Award (NIH), "Imaging of CNS Invasion by Venezuelan Equine Encephalitis Virus", **PI S Paessler**, no salary/effort, \$30,000 total from 09/01/2010-8/30/2011.

No number, Eutubics, Inc., "Adenovirus-based vaccines against influenza A," **PI S Paessler**, no salary/effort, \$52,000 total from 07/17/2009-30/06/2011.

1U01AI082103-01, National Institutes of Health (NIAID), "Non-invasive Optical Imaging of Select Agent Bacteria in Non-human Primates," PI: DM Estes, **Co-I: S Paessler**, 2% effort, \$450,000/year from 06/01/2009-05/30/2011.

5U19AI070489-02, Supplemental Award, Asthma and Allergic Diseases Cooperative Research Center (AADCRC), National Institutes of Health (NIAID), "Innate and Adaptive Immune Signaling in Asthma," PI: Holtzman, **PI for the subcontract S Paessler**, 5% effort, from 09/22/2009-08/31/2011.

5U19AI070489-02, National Institutes of Health (NIAID), "Innate and Adaptive Immune Signaling in Asthma," PI: Holtzman, **PI for the subcontract S Paessler**, 1% effort, \$38,000/year, from 08/15/2006-07/31/2011.

No number, Vaxart, Inc., "Novel vaccines against pandemic flu," **PI S Paessler**, no salary/effort, \$69,000 total from 04/17/2009-1/12/2011.

COMMITTEE RESPONSIBILITIES:

UTMB:

01/2005 – present	Biocontainment Risk and Safety Assessment Committee (IBC).
01/2005 – present	Community Advisory Committee (CAB).
06/2007 – present	Data Management Policy <i>ad hoc</i> Committee.
07/2008 – present	Institutional Animal Care and Use Committee (IACUC).
10/2011 – present	Student Examination Advisory Committee (SEAC).
10/2011 – present	Academic Enterprise Space Advisory Committee (AESAC)

TEACHING RESPONSIBILITIES AT UTMB:

06/2007 – present	Problem-Based Learning (PBL) Small Group Facilitator Cardiovascular Pulmonary Course (CVP). This is a ten-week commitment (56 hours) each summer.
12/2011 – present	Mock study section for proposals from graduate students, Experimental Pathology program.
10/2011 – present	Chair, Student Examination Advisory Committee (SEAC)
12/2011 – present	Chair, Preliminary Examination Committee for Meghan E. Hermance

Graduate and postdoctoral students presently supervised:

Gabriela Walker, D.V.M.	Postdoctoral fellow, 01/2008-present
Ivan Kurolt (Zagreb, Croatia)	Visiting/international Ph.D. student, 04/2008-present
Katherine Taylor	Ph.D. student, 08/2008-present (successfully defended)
Michael Patterson	Ph.D. student, 08/2009-present
Alexey Seregin	Ph.D. student, 05/2010-present
Olga Kolokoltsova	Ph.D. student, 07/2010-present
Shannon Ronca	Ph.D. student, 08/2012-present

John Manning

Ph.D. student, 08/2012-present

Other research personnel currently supervised:

Milagros Salazar, D.V.M. Senior biocontainment veterinarian, 06/2007-present

Jeanon Smith Laboratory manager, 11/2005-present

Medical students presently supervised:

Bobbie Thompson Laboratory training, 03/2007-present

Ph.D. Supervisory Committee Member:

Abdolali Danesh, 2011-present, external member at the University of Toronto, Toronto, Canada.

Tetyana Buzhdygan, 2012-present, external program member, Neuroscience program, UTMB.

Lidija Cvjetkovic, 2012-present, external program member, Microbiology, Medical School, Rijeka, Croatia.

Ivan Kurolt, 2013-present, external program member, Immunology, Medical School Zagreb, Croatia.

Graduate/postdoctoral students and other research personnel previously supervised:

Viktoriya Borisevich, Ph.D., Postdoctoral fellow, 07/2007-present

Michele Zacks, M.S., Ph.D., Graduate Student, 04/2006-06/2009

N. Seth Linde, Senior Animal Biocontainment Supervisor, 02/2005-05/2008

Andrea Berthke, Ph.D., Postdoctoral fellow, 07/2007-05/2008

Frances Valencia, rotation Ph.D. student (8-weeks), 2008

Kenneth Plante, rotation Ph.D. student (8-weeks), 2008

Natalia Dziuba, M.D., Postdoctoral fellow, 03/2006-11/2007

Haolin Ni, Ph.D., Research Associate, 03/2004-06/2007

Sven Enterlein, Ph.D., Postdoctoral fellow, 09/2006-11/2006

Henrike Grund, Ph.D., Postdoctoral fellow, 02/2006-09/2007

Trevor Pitcher, rotation Ph.D. student (8-weeks), 2007

Terence Hill, rotation Ph.D. student (8-weeks), 2007

Charles Scherer, D.V.M., 2007-2010.

Ashley Grant, 2009-2012.

Kathleen Taylor, 2008-2012.

Olga Chumakova, Ph.D., Research associate, 06/2007-present

Nadya Yun, M.D., Postdoctoral fellow, 02/2005-2011

Bi-Hung Peng, Ph.D. Postdoctoral fellow, 08/2007-2011

Jenna Linde Coordinator, 02/2006-present

Allison Poussard Animal biocontainment technician, 10/2007-present (now student at UTMB)

Jennifer Smith Animal biocontainment technician, 04/2006-2010

TEACHING AWARDS:

2012 Experimental Pathology Graduate Student Organization Award for Excellence in Graduate Teaching and Mentoring.

VISITING PROFESSORSHIP:

2013, Department of Immunology, Medical School of Kragujevac, Serbia.

MEMBERSHIP IN SCIENTIFIC AND PROFESSIONAL SOCIETIES:

2004 – present	American Society for Microbiology
2004 – present	American Society for Tropical Medicine & Hygiene
2005 – present	American Association for the Advancement of Science
2006 – present	American Society for Virology
2010 – present	European Society for Virology

EDITORIAL RESPONSIBILITIES:

Editorial Board:

Zoonoses and Public Health, 10/01/2007-present
Transboundary and Emerging Diseases (TBED)
formerly Journal of Veterinary Medicine, Series A, 12/2007-present
Journal of Pathogens, 2010-present
Journal of Virology & Antiviral Research, 2012-present

Guest Editor: PlosPathogens

Ad-hoc Reviewer:

American Journal of Tropical Medicine and Hygiene
Journal of General Virology
Journal of Virology
Virology
Vaccine
Archives of Virology
Microbiology and Molecular Biology Reviews
Veterinary Microbiology
PlosOne
PlosNeglected Diseases
PlosPathogens
Emerging Infectious Disease
Human Vaccines
Journal of Immunology

Clinical and Vaccine Immunology
Antimicrobial Agents and Chemotherapy (AAC)
Journal of Clinical Microbiology (JCM)
Antiviral Research
Science
New England Journal of Medicine (NEJM)

PATENTS:

Approved (U.S. Patent Office): Chimeric Sindbis-Eastern Equine Encephalitis Virus and Uses Thereof.
Application Number: 11/478,068. Filed: 06/29/2006

SERVICE FOR NATIONAL STUDY SECTIONS AND INTERNATIONAL ORGANIZATIONS

Reviewer for Biodefense Vaccine Enhancement BAA NIH-BARDA-NIAID-DMID-AI2007007. Review of contract proposals received in response to the Broad Agency Announcement (BAA) that addresses third generation anthrax vaccines as well as other category A and B pathogen vaccines. This is an important initiative since eventually these products will likely be considered for the National Stockpile.

Convener for the Workshop session titled "Vaccines & Vectors III." ASV annual meeting, 2008, Ithaca, NY.

Session Chair (neurovirology) for the 19th annual virology meeting (German Society for Virology), 2009, Leipzig, Germany.

Member, ViPR Scientific Working Group, NIH/NIAID 02/2010-present.

Special Volunteer at the Rocky Mountain Laboratory, Veterinary Division, NIAID/NIH, MT, USA. 03/2010-present.

Member, special emphasis panel to review R01/R21/R03 grant applications, NIAID/NIH, September 2011.

Reviewer for "Driving Biological Project proposals to NIAID Bioinformatics Centers" at ViPR, NIAID, December 6th 2011.

Member, study section to review R21/R33 grant applications for RFA-AI-11-032: "Host-Targeted Interventions as Therapeutics for Infectious Diseases".

Virology B study section, NIAID/NIH. From October 9-10 of 2012.

Member, Health and Medical Research Fund, Hong Kong Special Administrative Region, The People's Republic of China, December 2012.

SCIENTIFIC ADVISORY BOARD

Virus Pathogen Resource (ViPR) Scientific Working Group, NIH/NIAID, 2010-present.

COMMUNITY SERVICE

Basketball coach for children (6-8 years old), Christian Life Center, Moody Methodist Church, Galveston, TX.

Soccer coach for children (6-8 years old), Galveston County Youth Soccer League.

Scientific Research and Design: Bench Tutorials program 2011-2012 for the Ball High School, Galveston, TX.

BIBLIOGRAPHY

Articles in peer-reviewed journals:

1. **Paessler S** and Pfeffer M. Detection of antibodies to alphaviruses and discrimination between antibodies to eastern and western equine encephalitis viruses in rabbit sera using a recombinant antigen and virus-specific monoclonal antibodies. *J Vet Med B* 2003 50(6):265-269.
2. **Paessler S**, Fayzulin RZ, Anishchenko M, Greene IP, Weaver SC, Frolov I. Recombinant Sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. *J Virol* 2003 77(17):9278-9286.
3. Anishchenko M, **Paessler S**, Greene IP, Aguilar PV, Carrara AS, Weaver SC. Generation and characterization of closely related epizootic and enzootic infectious cDNA clones for studying interferon sensitivity and emergence mechanisms of Venezuelan equine encephalitis virus. *J Virol* 2004 78(1):1-8.
4. Weaver SC, Anishchenko M, Bowen R, Brault AC, Estrada-Franco JG, Fernandez Z, Greene I, Ortiz D, **Paessler S**, Powers AM. Genetic determinants of Venezuelan equine encephalitis emergence. *Arch Virol Suppl* 2004 (18):43-64.
5. **Paessler S**, Aguilar P, Anishchenko M, Wang HQ, Aronson J, Campbell G, Carrara AS, Weaver SC. The hamster as an animal model for eastern equine encephalitis--and its use in studies of virus entrance into the brain. *J Infect Dis* 2004 189(11):2072-2076.
6. Coffey LL, Carrara AS, **Paessler S**, Haynie ML, Bradley RD, Tesh RB, Weaver SC. Experimental Everglades virus infection of cotton rats (*Sigmodon hispidus*). *Emerg Infect Dis* 2004 10(12):2182-2188.
7. Greene IP, **Paessler S**, Anishchenko M, Smith DR, Brault AC, Frolov I, Weaver SC. Venezuelan equine encephalitis virus in the guinea pig model: evidence for epizootic virulence determinants outside the E2 envelope glycoprotein gene. *Am J Trop Med Hyg* 2005 72(3):330-338.
8. Carrara AS, Gonzales G, Ferro C, Tamayo M, Aronson J, **Paessler S**, Anishchenko M, Boshell J, Weaver SC. Venezuelan equine encephalitis virus infection of spiny rats. *Emerg Infect Dis* 2005 11(5):663-669.
9. Petrakova O, Volkova E, Gorchakov R, **Paessler S**, Kinney RM, Frolov I. Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in Mammalian cells. *J Virol* 2005 79(12):7597-7608.
10. Wang E, **Paessler S**, Aguilar PV, Smith DR, Coffey LL, Kang W, Pfeffer M, Olson J, Blair PJ, Guevara C, Estrada-Franco J, Weaver SC. A novel, Rapid Assay for Detection and Differentiation of Serotype-Specific Antibodies to Venezuelan Equine Encephalitis Complex Alphaviruses. *Am J Trop Med Hyg* 2005 72(6):805-810.
11. Greene IP, **Paessler S**, Austgen L, Anishchenko M, Brault AC, Bowen RA, Weaver SC. Envelope glycoprotein mutations mediate equine amplification and virulence of epizootic Venezuelan equine encephalitis virus. *J Virol* 2005 79(14):9128-9133.
12. Aguilar PV, **Paessler S**, Carrara A-S, Baron S, Poast J, Wang E, Moncayo AC, Anishchenko M, Watts D, Tesh RB, Weaver SC. Variation in interferon sensitivity and induction among strains of Eastern Equine Encephalitis virus. *J Virol* 2005 79(17):11300-11310.
13. **Paessler S**, Ni H, Petrakova O, Fayzulin RZ, Yun N, Anishchenko M, Weaver SC, Frolov I. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals

- vaccinated with chimeric SIN/VEE viruses. *J Virol* 2006 80(6):2784-2796.
14. Anishchenko M, Bowen RA, **Paessler S**, Austgen L, Greene IP, Weaver SC. Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. *Proc Natl Acad Sci USA* 2006 103(13):4994-4999.
 15. Wang E, **Paessler S**, Aguilar PV, Carrara AS, Ni H, Greene IP, Weaver SC. An RT-PCR-ELISA for rapid detection and differentiation of alphavirus infections. *J Clin Microbiol* 2006 44(11):4000-4008.
 16. Garmashova N, Gorchakov R, Volkova E, **Paessler S**, Frolova E, Frolov I. The Old World and New World alphaviruses use different virus-specific proteins for induction of the transcriptional shutoff. *J Virol* 2007 81(5):2472-2484.
 17. Ni H, Yun NE, Zacks MA, Weaver SC, Tesh RB, Travassos da Rosa A, Powers A, Frolov I, **Paessler S**. Recombinant alphaviruses are safe and useful serological diagnostic tools. *Am J Trop Med Hyg* 2007 76(4):774-781.
 18. Gorchakov R, Volkova E, Yun N, Petrakova O, Seth Linde N, **Paessler S**, Frolova E, Frolov I. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. *Virology* 2007 366(1):212-225.
 19. **Paessler S**, Yun N, Judy BM, Dziuba N, Zacks MA, Grund AH, Frolov I, Campbell GA, Weaver SC, Estes DM. Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. *Virology* 2007 367(2):307-323.
 20. Wang E, Petrakova O, Adams AP, Aguilar PV, Kang W, **Paessler S**, Frolov I, Weaver SC. Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. *Vaccine* 2007 25(43):7573-7581.
 21. Zacks MA and **Paessler, S**. Alphavirus-based chimeric vaccines against encephalitic alphaviruses (Expert Review). *Croatian Journal of Infection*. 2007 27(4):155-160.
 22. Rosas C, **Paessler S**, Ni H. Perkins GA, Goodman LB, Metzger SM, and Osterrieder N. Development of a modified-live virus combination vaccine against infections with equine herpesvirus type 1 (EHV-1) and Venezuelan equine encephalitis virus (VEEV). *Am J Trop Med Hyg*. 2007 78(1):83-92.
 23. Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L, Kilpatrick JM, Arnold S, and **Paessler S**. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with highly virulent H5N1 influenza virus isolate A/Vietnam/1203/04. *Virology* 2008 374(1):198-209.
 24. **Paessler S**, Ni H, Yun NE, Stein D and Rijnbrand C. Peptide-conjugated phosphorodiamidate morpholino oligomers inhibit alphavirus replication and prevent lethal encephalitis in VEEV-infected mice. *Virology* 2008 376(2):357-370.
 25. Kendirgi F, Yun NE, Linde N, Zacks MA, Jeanon Smith, Jennifer Smith, McMicken H, Chen Y, **Paessler S** "A Novel DNA-based vaccine protects mice against lethal infection with H5N1 influenza virus." *Hum Vaccin* 2008 4(5):410-419.
 26. Yun NE, Linde NS, Dziuba N, Zacks MA, Smith JN, Smith JK, Aronson JF, Chumakova OV, Lander HM, Peters CJ, **Paessler S**. "Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs." *Am J Trop Med Hyg*. 2008 Aug;79(2):275-282.
 27. Whitlock GC, Lukaszewski RA, Judy B, **Paessler S**, Torres AG, and Estes MD. Host lymphocyte, cytokine and complement participation in the protective response to vaccination with heat-killed *Burkholderia mallei*. *BMC Immunol* 2008 9:55.
 28. Espinosa BJ, Weaver SC, **Paessler S**, Brining D, Salazar M and Kochel T. "Susceptibility of the *Aotus nancymae* owl monkey to Eastern Equine Encephalitis." *Vaccine*. 2009 27(11):1729-1734.

29. Yun NE, Peng BH, Bertke AS, Borisevich V, Smith JK, Smith JN, Poussard AL, Salazar M, Judy BM, Zacks MA, Estes DM, **Paessler S**. "CD4(+) T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus." *Vaccine* 2009 27(30):4064-4073.
30. Song L, Zhang Y, Yun NE, Poussard AL, Smith JN, Smith JK, Borisevich V, Linde JJ, Zacks MA, Li H, Kavita U, Reiserova L, Liu X, Dumuren K, Balasubramanian B, Weaver B, Parent J, Umlauf S, Liu G, Huleatt J, Tussey L, **Paessler S**. "Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin." *Vaccine*. 2009 Sep 25;27(42):5875-84.
31. Zacks MA and **Paessler S**. "Equine Encephalitides." Invited review for *Veterinary Microbiology* (a special issue on zoonoses). *Vet Microbiol*. 2010 Jan 27;140(3-4):281-6. Epub 2009 Aug 28. Review.
32. **Paessler S** and Weaver SC., Vaccines for Venezuelan equine encephalitis, *Vaccine*. 2009 Nov 5;27 Suppl 4:D80-5.
33. Estes DN, Zacks MA and **Paessler S**. "Evaluation of host responses to vaccination and infection with Venezuelan Equine Encephalitis Virus (VEEV)". *Current Trends in Immunology* 2009, Vol 10; page 61-71.
34. A Seregin, N Yun and **Paessler S**. "TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs." *Vaccine*. 2010 Jul 5;28(30):4713-8. Epub 2010 May 7.
35. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, Salazar MS and **Paessler S**. "Mice lacking interferon α/β and γ receptors are susceptible to Junin virus infection". *J Virol*. 2010 Dec;84(24):13063-7.
36. Urata S, Yun N, **Paessler S**, Kunz S, and de la Torre JC. "Antiviral activity of a small molecule inhibitor of arenavirus glycoprotein processing by the cellular Site 1 Protease." *J Virol*. 2011 Jan;85(2):795-803.
37. Emonetax S, Seregin A, Yun NE, Poussard A, Walker A, de la Torre JC and **Paessler S**. "Rescue From Cloned cDNAs And In Vivo Characterization of Recombinant Pathogenic Romero And Life Attenuated Candid #1 Strains Of Junin Virus, The Causative Agent Of Argentine Hemorrhagic Fever Disease". *J Virol*. 2011 Feb;85(4):1473-83.
38. Welte T, Aronson J, Gong B, Mendell N, Rachamalla A, Tesh R, **Paessler S**, Born W, O'Brien R, and Wang T. "V γ 4+ T Cells Suppress V γ 1+ T cell Response During West Nile Virus Infection." *FEMS Immunol Med Microbiol*. 2011 Nov;63(2):183-92.
39. Peng B, Yun N and **Paessler S**. "Neuroinflammatory model for H5N1 influenza A infection in ferrets". *Vet Microbiol*. 2012 May 4;156(3-4):294-304. doi: 10.1016/j.vetmic.2011.11.025. Epub 2011 Dec 2.
40. Jones FR, Gabitzsch ES, Xua Y, Borisevich V, Smith J, Peng B, Walker A, **Paessler S**. "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine." *Vaccine*. 2011 Sep 16;29(40):7020-6. Epub 2011 Aug 5.
41. M Salazar, N Yun, AL Poussard, JN Smith, JK Smith, O Kolokoltsova, MJ Patterson, J Linde, M Zacks and **S Paessler**. "Ribavirin promotes survival in guinea pigs infected with Junin virus." *Zoonoses Public Health*. 2012 Jan 2. doi: 10.1111/j.1863-2378.2011.01447.x. [Epub ahead of print]
42. Patterson M, Poussard A, Taylor K, Seregin A, Smith J and **Paessler S**. "Rapid, non-invasive imaging of alphaviral brain infection: Reducing animal numbers and morbidity to identify efficacy of potential vaccines and antivirals. *Vaccine*. 2011 Nov 21;29(50):9345-51. Epub 2011 Oct 12.
43. Yun NE, Poussard AP, Seregin AV, Walker AG, Smith JK, Aronson JF, Smith JN, Soong L and **Paessler S**. "Functional interferon system is required for clearance of Lassa virus". *J Virol*. 2012 Mar;86(6):3389-92. Epub 2012 Jan 11.

44. Taylor K, Patterson M, Poussard A, Estes DM and **Paessler S**. "Natural Killer Cell mediated pathogenesis determines outcome of central nervous system infection with Venezuelan equine encephalitis in C3H/HEN mice. *Vaccine*. 2012 Jun 8;30(27):4095-105. Epub 2012 Apr 21.
45. Huan C, Kolokoltsova OA, Yun NE, Poussard AL, Brasier A, **Paessler S**. "Argentine Hemorrhagic Fever Virus infection activates type I Interferon pathway in a RIG-I-dependent manner." *PLoS Negl Trop Dis*. 2012 May;6(5):e1659. Epub 2012 May 22.
46. Kuroit IC, **Paessler S**, Markotić A. "Resequencing of the Puumala virus strain Sotkamo from the WHO Arbovirus collection." *Virus Genes*. 2012 Jul 15. [Epub ahead of print]
47. Grant A, Seregin A, Huang C, Kolokoltsova OA, Brasier A and **Paessler S**. "Junin Virus Pathogenesis and Virus Replication". *Viruses* 2012, 4, 2317-2339; doi:10.3390/v4102317
48. **Paessler S**. and Walker DH. "Mechanisms of Disease: Viral Hemorrhagic Fevers". *Annu Rev Pathol*. 2012 Nov 1. [Epub ahead of print]
49. Gabitzsch ES, Balint-Junior JP, Xu Y, Balcaitis S, Sanders-Ber B, Karl J, Weinhold KJ, **Paessler S**, Jones FR. "Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform". *Vaccine*. 2012 Nov 26;30(50):7265-70. doi: 10.1016/j.vaccine.2012.09.058. Epub 2012 Oct 2.
50. Poussard, A., Patterson, M., Taylor, K., Seregin, A., Smith, J., Smith, J and **Paessler S**. In Vivo Imaging Systems (IVIS) Detection of a Neuro-Invasive Encephalitic Virus. *J. Vis. Exp.* (70), e4429, doi:10.3791/4429 (2012).
51. Peng B, Borisevich V, Zacks M, Estes D and **Paessler S**. "Production of IL-8, IL-17, IFN-gamma and IP-10 in human astrocytes correlates with alphavirus attenuation." Accepted, *Veterinary Microbiology*.
52. Tian B, Zhao Y, Kalita M, Edeh C, **Paessler S**, Casola A, Garofalo R, and Brasier A. "CDK9-dependent transcriptional elongation in the innate ISG response to RSV infection in airway epithelial cells". *J Virol*. 2013 Jun;87(12):7075-92. doi: 10.1128/JVI.03399-12. Epub 2013 Apr 17.
53. Yun NE, Seregin AV, Walker DH, Popov VL, Walker AG, Smith JN, Miller M, de la Torre JC, Smith JK, Borisevich V, Fair JN, Wauquier N, Grant DS, Bockarie B, **Paessler S**. "Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus." *J Virol*. 2013 Jul 31. [Epub ahead of print].
54. **Paessler S** and Katherine Taylor. "Pathogenesis of VEEV." Accepted, *Veterinary Microbiology*.
- 55.

Manuscripts in review/preparation:

Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, Salazar MS and **Paessler S**. "Junin virus infection leads to apoptosis in human cells." In revision, *Journal of Virology*.

Agapov E, Tidwell R, Hinojosa ME, Patel AC, **Paessler S**, Atkinson J, and Holtzman MJ. "Influenza A Virus Remains Active and Causes Chronic Disease in the Lung." In review, *PlosPathogens*.

Hyde JL, Gardner CL, Kimura T, White JP, Trobaugh DW, Huang C, Szretter KJ, **Paessler S**, Takeda K, Amarasinghe GK, Klimstra WB, and Diamond MS. "A viral RNA structural element antagonizes cell-intrinsic immunity". In review, *Science*.

Koma T, Huang C, Kolokoltsova O and **Paessler S**. "Innate immune response to New World Arenaviruses". Invited Review, *Journal of Molecular Biology*.

Paessler S. Invited review for *Antiviral Research*: "Antiviral strategies against hemorrhagic arenaviruses". In preparation.

Book chapters:

1. Pfeffer M and **Paessler S**. "Venezuelan equine encephalitis virus" in Janata O, Reisinger EC (Hrsg.) Infektiologie Aktuelle Aspekte, Jahrbuch 2003/2004.
2. **Paessler S** and Pfeffer M. "Togaviruses causing encephalitis (Togaviridae)" in Encyclopedia of Virology, 3rd Edition, Editors-in-Chief, Brian Mahy and Marc Van Regenmortel, Elsevier (2008).
3. Weaver SC and **Paessler S**. "Alphaviral vaccines" in Vaccines for Biodefense and Emerging and Neglected Diseases, 1st Edition, Publisher, Life Sciences, Elsevier. Pub. Date: January 2009
4. Zacks M. and **Paessler S**. Global View at Fight against Influenza. Nova Science Pub Inc., Pub. Date: 7/1/2009
5. **Paessler S**. Hunters - Tropical Medicine and Emerging Infectious Diseases 9E. "Hemorrhagic New World Arenaviruses". (Chapter for the 9th Edition).
6. **Paessler S** and Katherine Taylor. Encephalitis: Chapter title "Current developments in alphaviral encephalitis", Intech 2011.
7. **Paessler S** and Katherine Taylor. Neuroviral infections; Chapter title "Alphaviruses and CNS infections", Taylor and Francis 2011.

PRESENTATIONS:

Invited Seminars:

1. **Paessler S**, Frolov I, Weaver SC. Chimeric alphaviruses for serological diagnostics. The Future of the Biomedical Research Industry in Texas. **Galveston, Texas**, 2004.
2. **Paessler S**, Weaver SC, Frolov I. VEE pathogenesis and vaccine development. 4th Croatian Congress on Infectious Diseases. **Opatija, Croatia**, 2004.
3. **Paessler S**, Weaver SC, Frolov I. Chimeric alphaviruses for serological diagnostics. Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research Annual Meeting, University of Texas Southwestern Medical Center, **Dallas, Texas**, 2004.
4. **Paessler S**, Ni H, Weaver SC, Frolov I. Chimeric alphaviruses as diagnostic tools. NIH/NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research 2nd Annual Meeting, Moody Gardens, **Galveston, Texas**, 2005.
5. **Paessler S**, Weaver SC, Frolov I, Ni H, Aronson J. Protective mechanisms of alphavirus vaccines. NIH/NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research 2nd Annual Meeting, Moody Gardens, **Galveston, Texas**, 2005.
6. **Paessler S**. Morpholino antisense drugs against VEEV. Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Annual Meeting, University of Texas at San Antonio, **San Antonio, Texas**, 2005.
7. **Paessler S**. Chimeric alphaviruses for serological VEEV diagnostics. Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Annual Meeting, University of Texas at San Antonio, San Antonio, Texas, 2005.
8. **Paessler S**. Chimeric Alphaviruses for Serological Diagnostics. NIH/NIAID Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Diagnostics Development Workshop, Columbia University, **New York, New York**, 2006.
9. **Paessler S**. Impact of selective lymphoid deficiencies on encephalitis and virus persistence in the murine brain. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, **Ithaca, New York**, 2006.

10. **Paessler S.** VEE vaccine development. 5th Croatian Congress on Infectious Diseases. **Zadar, Croatia**, 2006.
11. **Paessler S.** Avian influenza (H5N1) animal models and antivirals. Biocryst, **Birmingham, AL**, 2007.
12. **S. Paessler.** Vaccine Development against encephalitic alphaviruses. 11th Medical B Defence Conference, **Munich, Germany**, 2007.
13. **S. Paessler.** Avian influenza: Beyond flu like symptoms in two animal models. Medical School, **Zagreb, Croatia**, 2008.
14. **S. Paessler.** Alphavirus based vaccine development against encephalitic and hemorrhagic fever viruses. Vaccine & Gene Therapy Institute, Oregon Health & Science University, **Portland, Oregon**. 2008.
15. **S. Paessler.** VEEV pathogenesis and vaccine development, Oregon State University, **Corvallis, Oregon**, 2008.
16. **Paessler, S.** VEEV-modulated expression of cytokines and chemokines in the CNS. International Neuroimmunology Symposium. International Neuroimmunology Symposium, **Dublin, Ireland**, 2008.
17. **Paessler, S.** VEEV pathogenesis. Tufts University, **North Grafton, MA**, November 2008.
18. **Paessler, S.** VEEV pathogenesis. University of California, **Davis, CA**, December 2008.
19. **Paessler, S.** CD40-ligand dependent protection against VEEV, **Leipzig, Germany**, March 2009.
20. **Paessler, S.** Avian Influenza: "Beyond flu-symptoms in two animal models", Vertex Inc, **Boston, MA**, April 2009.
21. **Paessler S.** VEEV pathogenesis. Keynote speaker for the annual retreat at the Department of Microbiology and Immunology at the Veterinary College, Cornell University, Ithaca, NY, March 2009.
22. **Paessler S.** Neuroinflammation caused by zoonotic RNA viruses. Free University Berlin, **Berlin, Germany** 2009.
23. **Paessler S.** Alphavirus-vectored vaccines against zoonotic pathogens. Croatian Microbiology Association, **Sibenik, Croatia**, 2009.
24. **Paessler S.** Host response to infection with arenaviruses. ASM Texas Branch meeting at **UT Tyler, TX**, 11/2009.
25. **Paessler S.** Host response to infection with arenaviruses. NIH/RML, **Hamilton, MT**, 2010.
26. **Paessler S.** Recombinant genetics for Arenaviruses. Invited speaker for a workshop at MITRE, Department of Defense, **Washington, DC**, 2010.
27. **Paessler S.** Molecular pathogenesis of Arenaviruses. Invited speaker for the Western Regional Center for Excellence in Biodefense, **Houston, TX**, November 2010.
28. **Paessler S.** Recombinant genetics for Arenaviruses. Invited speaker for the National RCE meeting in Denver, April 2011. Chair of the session "Hemorrhagic fever viruses".
29. **Paessler S.** Recombinant genetics for Arenaviruses. Invited speaker for a Biodefense symposium, **Munich, Germany, October** 2011.
30. **Paessler S.** Cellular response to arenaviruses, Scynexis, Research Triangle, NC.
31. **Paessler S.** Cellular response to hemorrhagic arenaviruses, invited speaker at the University of Toronto, Toronto, Canada, March 1st 2012.
32. **Paessler S.** Pathogenesis of arenaviruses, keynote speaker at the Rocky Mountain Regional Center of Excellence in Biodefense, Missoula, MT, October 2012.

33. **Paessler S.** Recombinant genetics for arenaviruses, Utah State University, USA, March 2013.
34. **Paessler S.** Host response to arenavirus infection, Kansas State University, USA, May 2013.
35. **Paessler S.** Host response to arenavirus infection, Kragujevac University, Serbia, June 2013.
36. **Paessler S.** Reprogramming encephalitic response, "One Health Symposium", Humboldt University Berlin, Germany.

Other Presentations:

1. **Paessler S** and Pfeffer M. Epitope-Blocking-Assay for detection of Alphavirus-genus, WEEV-serocomplex and EEEV-serocomplex specific antibodies using monoclonal antibodies and recombinant antigens. Conference for Positive-Strand RNA Viruses, **Paris, France**, 2001.
2. Carrara A, Moncayo A, Ferro MC, Gonzales M, **Paessler S**, Aronson J, Boshell J, and Weaver SC. Pathogenesis of Venezuelan Equine Encephalitis Virus on the enzootic rodent reservoir. The American Society of Tropical Medicine and Hygiene 51st annual meeting, **Denver, Colorado**, 2002.
3. Carrara A, Moncayo A, Ferro MC, Kang W, **Paessler S**, Aronson J, Boshell J, and Weaver SC. Pathogenesis of VEE in rodent reservoir. Gulf Coast Tropical Medicine Association meeting, **Galveston, Texas**, 2002.
4. Greene IP, **Paessler S**, Weaver SC. A Novel Model for Comparison of Epizootic versus Enzootic VEE pathogenesis. Poster presentation at the Department of Pathology, UTMB, Research Day, **Galveston, TX** 2003. *Received award for best poster by graduate student in the pathologic/clinical applied research category.*
5. **Paessler S**, Aguilar P, Anishchenko M, Wang HQ, Aronson J, Campbell G, Cararra A, and Weaver SC. Golden hamster as an animal model for EEEV-induced vasculitis/encephalitis and its use to study virus entrance into the brain. Poster presentation at the Department of Pathology UTMB, Research Day, **Galveston, TX** 2003. *Received award for best poster by post-doctoral fellows in the pathologic/clinical-applied sciences.*
6. Anishchenko M, **Paessler S**, Smith D, and Weaver SC. A unique model for investigation of genetic determinants of VEE virus emergence and its application for pathogenesis studies. Poster presentation at the Department of Pathology, UTMB, Research Day, **Galveston, TX** 2003. *Received award for best poster by post-doctoral fellow in molecular/cell biology research.*
7. Weaver SC, Bowen R, Brault AC, Fernandez Z, Estrada-Franco JG, Greene I, Ortiz D, **Paessler S**, and Powers AM. Genetic Determinants of Venezuelan Equine Encephalitis Emergence: Emergence and Control of Zoonotic Viral Encephalitis. **Annecy, France**, 2003.
8. Aguilar P, **Paessler S**, and SC Weaver. Interferon sensitivity and induction and correlations with virulence among Eastern Equine Encephalitis viruses. 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Philadelphia, Pennsylvania**, 2003.
9. Anishchenko M, **Paessler S**, Austgen L, Bowen RA, Greene IP, Powers AM, and Weaver SC. Generation of the Epizootic Phenotype of Venezuelan Equine Encephalitis Virus via Mutations in a Subtype ID Enzootic Strain. 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Philadelphia, Pennsylvania**, 2003.
10. Aguilar P, **Paessler S**, Baron S, Poast J, Wang E, Anishchenko M, Weaver SC. Differences in Interferon Sensitivity and Induction and their Correlation with Virulence Among Strains of Eastern Equine Encephalitis Virus. 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Philadelphia, Pennsylvania**, 2003.
11. **Paessler S**, Fayzulin RZ, Anishchenko M, Greene IP, Weaver SC, and Frolov I. Recombinant

- Sindbis/ Venezuelan equine encephalitis virus is highly attenuated and immunogenic. Merleux Foundation, Emergence & Control of Zoonotic Viral Encephalitis, **Geneva, Switzerland**, 2003.
12. **Paessler S**, Weaver SC, Frolov I. VEE Pathogenesis and Vaccine Development. 4th Croatian Congress on Infectious Diseases, **Opatija, Croatia**, 2004.
 13. Smith DR, **Paessler S**, and Weaver, SC. IFN α/β Mediates the Tissue Tropism of VEE in a Murine Model. European Congress on Virology, **Madrid, Spain**, 2004.
 14. Carrara, A., Coffey L, **Paessler S**, Aronson J, and Weaver SC. Comparison of two geographical populations of cotton rat experimentally infected with Venezuelan equine encephalitis virus. EID, **Atlanta, Georgia**, 2004.
 15. Anishchenko M., **Paessler S**, Bowen RA, Austgen L, and Weaver SC. Generation of Epizootic VEEV Strains via Mutations in an Enzootic ID Progenitor. 7th International Symposium on Positive Strand RNA Viruses, **San Francisco, California**, 2004.
 16. Carrara A, Coffey L, Smith D, **Paessler S**, Anishchenko M, Aguilar P, Kang W, Aronson J, and Weaver SC. Comparison of two geographic populations of cotton rats experimentally infected with Venezuelan equine encephalitis virus. Gulf Coast Tropical Medicine Association, **Galveston, Texas**, 2004.
 17. Aguilar P, Carrara A, **Paessler S**, Aronson J, Rynbrand R, Travassos da Rosa A, Watts D, Tesh R, and Weaver SC. Phenotypic characterization of newly identified avirulent strain of eastern equine encephalitis virus in the murine model. McLaughlin Symposium on Infection and Immunity, **Galveston, Texas**, 2004.
 18. Coffey L, Carrara A, **Paessler S**, Haynie M, Bradley R, Tesh R, and Weaver SC. Experimental Everglades virus infection of cotton rats (*Sigmodon hispidus*) from endemic and non-endemic areas. 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Miami, Florida**, 2004.
 19. **Paessler S**, Ni H, Yun N, Stein D, and Rijnbrand C. Peptide-conjugated phosphorodiamidate Morpholino oligomers inhibit alphavirus replication and prevent lethal encephalitis in VEEV-infected mice. 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Washington, DC**, 2005.
 20. **Paessler S**, Gorchakov R, Yun N, Linde NS, and Frolov I. Alphavirus-based vaccines against Rift Valley Hemorrhagic Fever Virus. 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Washington, DC**, 2005.
 21. Zacks, MA, Dziuba N, Ni H, Frolov I, Campbell GA, Yun N, Weaver SC, Estes DM, and **Paessler S**. Persistence of attenuated variants of Venezuelan equine encephalitis virus (VEEV) in the murine brain. 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Washington, DC**, 2005.
 22. **Paessler S**, Yun N, Ni H, Judy BM, Dziuba N, Zacks MA, Frolov I, Campbell GA, Weaver SC, and Estes DM. Impact of selective lymphoid deficiencies on encephalitis and virus persistence in the murine brain (VEEV). 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Washington, DC**, 2005.
 23. Ni H, Yun N, Zacks M, Weaver SC, Tesh RB, Travassos da Rosa APA, Powers AM, Frolov I, **Paessler S**. Recombinant alphaviruses are safe and useful serological diagnostic tools. 3rd Annual Meeting of the Regional Centers for Biodefense and Emerging Infectious Diseases Research, **New York, New York**, 2006.
 24. Ni H, Yun N, Zacks MA, Weaver SC, Tesh RB, Travassos da Rosa AP, Powers AM, Frolov I, **Paessler S**. Recombinant alphaviruses are safe and useful serological diagnostic tools. 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene, **Washington, DC**, 2005.
 25. **Paessler S**, Yun NE, Ni H, Judy BM, Dziuba N, Zacks MA, Frolov I, Campbell GA, Weaver SC and

- Estes DM. Impact of selective lymphoid deficiencies on encephalitis and virus persistence in the murine brain (VEEV). Poster presentation at the 55th Annual Meeting of the American Society for Tropical Medicine and Hygiene, **Atlanta, Georgia**, 2006.
26. **Paessler S**, Yun NE, Ni H, Judy BM, Zacks MA, Dziuba N, Frolov I, Campbell GA, Weaver SC and Estes DM. Role of CD4+ and CD8+ T cells in protection against lethal encephalitis mediated by a Sindbis-VEEV chimeric vaccine. Poster presentation at the 55th Annual Meeting of the American Society for Tropical Medicine and Hygiene, **Atlanta, Georgia**, 2006.
 27. Yun NE, Linde NS, Zacks MA, Dziuba N, Smith JN, Grund H, **Paessler S**. Peramivir mitigates disease and promotes survival in ferrets and mice infected with H5N1 influenza virus isolate A/Vietnam/1203/04. Poster presentation at the 55th Annual Meeting of the American Society for Tropical Medicine and Hygiene, **Atlanta, Georgia**, 2006.
 28. Grund, AH, Yun NE, Linde NS, Kelley MJ, **Paessler S**. Cytokine Expression in Brain Tissue of VEEV-Infected Mice. Poster presentation at the 55th Annual Meeting of the American Society for Tropical Medicine and Hygiene, **Atlanta, Georgia**, 2006.
Arnold CS, Zacks MA, Dziuba N, Yun N, Linde N, Smith J, Babu YS, **Paessler S**. Injectable peramivir is effective in the treatment of highly pathogenic avian influenza A/Vietnam/1203/04 (H5N1) infections in mouse and ferret models. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. **San Francisco, California**, 2006.
 29. **Paessler S**, Gorchakov R, Yun NE, Linde NS, Zacks MA, and Frolov I. Alphavirus-based vaccines against Rift Valley hemorrhagic fever virus. The Changing Landscape of Vaccine Development: Vaccines for Global Health. **Galveston, Texas**, 2006.
 30. **Paessler S**, Yun NE, Ni H, Judy BM, Dziuba N, Zacks MA, Frolov I, Campbell GA, Weaver SC and Estes DM. Impact of selective lymphoid deficiencies on encephalitis and virus persistence in the murine brain (VEEV). The Changing Landscape of Vaccine Development: Vaccines for Global Health. **Galveston, Texas**, 2006.
 31. **Paessler S**, Gorchakov R, Yun NE, Linde NS, Zacks MA, and Frolov I. Alphavirus-based vaccines against Rift Valley fever virus. International Meeting on Emerging Diseases and Surveillance. **Vienna, Austria**, 2007.
 32. **Paessler S**, Yun NE, Ni H, Judy BM, Dziuba N, Zacks MA, Frolov I, Campbell GA, Weaver SC and Estes DM. Development of a live-attenuated, chimeric alphavirus-based vaccine against Venezuelan equine encephalitis virus. International Meeting on Emerging Diseases and Surveillance. **Vienna, Austria**, 2007.
 33. Amberg SM, Larson RA, Allen RD, Dai D, Jones KF, Lebsack K, Warren TK, King DS, Berhanu A, **Paessler S**, Cashman KA, Guttieri MC, Carrion Jr. RC, Bolken TC, Hruby DE. Identification and evaluation of a broad-spectrum arenavirus inhibitor. American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
 34. Allen III RD, Kickner SS, SPerzel LE, VanderMay EN, Katrich V, Dai D, Jones KF, Lebsack K, Warren TK, King DS, Berhanu A, Yun NE, **Paessler S**, Amberg SM, Bolken TC, Hruby DE. *In Vitro* and *In Vivo* Characterization of the New World Arenavirus Inhibitor, ST-294, and Related Analogues. American Society for Virology 26th Annual Meeting. July 14-18, 2007. Oregon State University, **Corvallis, Oregon**.
 35. Dziuba N, Bourne K, Yun NE, Estes DM, Zacks MA, **Paessler S**.
 36. Ex vivo model of inflammatory response to alphavirus infection. American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
Paessler S, Ni H, Yun NE, Stein D, Rijnbrand C. Peptide-conjugated phosphorodiamidate morpholino oligomers inhibit alphavirus replication and prevent lethal encephalitis in VEEV-infected

- mice. American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
37. Yun NE, Ni H, Judy BM, Dziuba N, Zacks MA, Grund AH, Frolov I, Campbell GA, Weaver SC, Estes DM, **Paessler S**. Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
 38. Amberg, S.M., Larson, R.A., Allen III, R.D., Dai, D., Jones, K.F., Lebsack, K., Warren, T.K., King, D.S., **Paessler, S.**, Yun, N., Cashman, K.A., Guttieri, M.C., Carrion, Jr., R., Brasky, K., Patterson, J.L., Bolken, T.C., Hruby, D.E. Identification and evaluation of a broad-spectrum arenavirus inhibitor American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
 39. Allen III, R.D., Kickner, S.S., Sperzel, L.E., VanderMay, E.N., Larson, R.A., Nelson, D.A., Katrich, V., Dai, D., Jones, K.F., Lebsack, K., Warren, T.K., King, D.S., Yun, N., Paessler, S., Amberg, S.M., Bolken, T.C., Hruby, D.E. In vitro and in vivo characterization of the New World arenavirus inhibitor, ST-294, and related analogues. American Society for Virology 26th Annual Meeting. Oregon State University, **Corvallis, Oregon**, 2007.
 40. Espinosa B, Weaver S, **Paessler, S**, Brining D, Salazar M, Kochel T. Evaluation of the *Aotus nancymae* New World monkey as an animal model for Eastern Equine Encephalitis. Submitted to the American Society of Tropical Medicine and Hygiene for presentation at the 56th Annual Meeting, **Philadelphia, Pennsylvania**, 2007.
 41. Alexey V Seregin, Nadezhda E Yun and **Paessler S**. Alphavirus Vector-based Vaccine Development against Argentine Hemorrhagic Fever. Vaccine 2nd Congress. **Boston, MA**, 2008.
 42. N.E. Yun, A.S. Bertke, M.A. Zacks, N.S. Linde, J.K. Smith, A.L. Poussard, V Borisevich, B.M. Judy and **Paessler S**. Role of CD4+ and CD8+ T Cells in Protection against Lethal Encephalitis Mediated by a Sinbis-VEEV Chimeric Vaccine. Vaccine 2nd Congress. **Boston, MA**, 2008”
 43. Borisevich V, Seregin A, Yun N.E, Rijnbrand R, Stein D.A, Ma Y; Blouch, R, Iversen P.L, Zacks M.A, **Paessler S**. Dose-dependent inhibition of VEEV infection with morpholino oligomers. American Society for Virology 27th annual meeting (Oral presentation). Cornell University, Ithaca, New York, USA July 12-16, 2008.
 44. Nadezhda E. Yun, Nathaniel S. Linde, Michele A. Zacks, Ian G. Barr, Aeron C. Hurt, Jeanon N. Smith, Natallia Dziuba, Michael R. Holbrook, Lifang Zhang, John M. Kilpatrick, C. Shane Arnold, and **Paessler S**. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent TYPE A/H5N1 influenza virus. The American Society for Virology 27th annual meeting. **Ithaca, NY**, 2008.
 45. Bertke A.S., Yun N.E., Dziuba N., Linde N.S., Smith J.K., Poussard A.L., Judy B.M., Zacks M.A., Estes D.M., **Paessler S**. Role of CD4+ and CD8+ T cells in protection against Venezuelan equine encephalitis. The American Society for Virology 27th annual meeting. **Ithaca, NY**, 2008.
 46. Peng BH, Yun N.E, Eates M, Judy B.M, Zacks M.A, Borisevich V, Popov V, **Paessler S**. Chemokine secretion in Venezuelan equine encephalitis virus-infected astrocytes. ASV 27th annual meeting (Poster). Cornell University, Ithaca, New York, USA July 12-16, 2008.
 47. **Paessler S**, R.V. Gorchakov, N.E. Yun, M.A. Zacks, I.V. Frolov. Alphavirus-Vectored Avian Influenza Vaccine Provides a High Level of Protection against Avian Influenza Type A H5N1. The 10th Annual McLaughlin Symposium. Galveston, TX, 2009.
 48. Olga A. Kolokoltsova, Nadezda E. Yun, Allison L. Poussard, Jennifer K. Smith, Jeanon N. Smith, Magda S. Salazar gross, Walker Aida, **Paessler S**. Transcriptional profile of Junin virus infection in human glial cells: Role of innate immunity in pathogenesis of hemorrhagic arenavirus. Keystone Symposia of Molecular and Cellular Biology, Innate Immunity: Mechanisms Linking with Adaptive Immunity, **Dublin, Ireland**, 2010.

49. Olga A. Kolokoltsova, Nadezda E. Yun, Allison L. Poussard, Jennifer K. Smith, Jeanon N. Smith, Magda S. Salazar gross, Judith F. Aronson, Walker Aida, **Paessler S.** Mouse resistance to Junin virus infection is dependent on functional interferon signaling. The American Society for Virology, 29th Annual Meeting, **Bozeman, Montana**, 2010.
50. Olga A. Kolokoltsova, Nadezda E. Yun, Allison L. Poussard, Jennifer K. Smith, Walker Aida, Slobodan Paessler. The significance of induction of type I IFN and programmed cell death for Junin virus attenuation. Department of Pathology, 17th Annual Research Day. April 26, 2011. University of Texas Medical Branch, Galveston, Texas.
51. Nadezhda Yun, Allison Poussard, Alexey Seregin, Aida Walker, Jennifer Smith, Jeanon Smith, Judith Aronson, **Paessler S.** Dependence of Lassa virus on functional IFN-mediated immune response. The American Society for Virology, 30th Annual Meeting, Minneapolis, Minnesota, 2011.